The Phase 3 PEACE-3 study has investigated the efficacy and safety of combining enzalutamide (ENZA) with radium-223 (Ra-223) in patients with androgen receptor pathway inhibitor (ARPI)-naive metastatic castration-resistant prostate cancer (mCRPC). The trial's design and objectives centered on evaluating the impact of this combination on radiographic progression-free survival (rPFS) and overall survival (OS).
Efficacy Data
Dr. Evan Y. Yu discussed the key efficacy findings from the PEACE-3 study, emphasizing the impact of the enzalutamide and radium-223 combination on rPFS and OS. These results are intended to inform clinical decision-making regarding treatment strategies for mCRPC, offering a potential new approach for patients who have not previously been treated with ARPIs.
Safety Profile
In addition to efficacy, the PEACE-3 study closely monitored the safety of the combination therapy. Dr. Yu also presented safety data, highlighting key outcomes such as the incidence of adverse events and treatment-related toxicities. Special attention was given to potential concerns related to bone health and hematologic function, which are critical considerations when using radium-223.
The comprehensive assessment of both efficacy and safety in the PEACE-3 trial aims to provide clinicians with a clearer understanding of the potential benefits and risks associated with combining enzalutamide and radium-223 in the treatment of mCRPC. Further analysis and long-term follow-up will be essential to fully characterize the role of this combination in the evolving treatment landscape for metastatic castration-resistant prostate cancer.
